Ascend Capital’s Assembly Biosciences ASMB Stock Holding History

Ascend Capital’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-873	Closed	-$514K	–	176
2018 Q1	$514K	Buy	+873	New	+$541K	0.02%	198

Other funds holding ASMB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ascend Capital's ASMB Position: Q2 2018 in Review

Ascend Capital sold out of Assembly Biosciences (ASMB) in Q2 2018, closing a stake of 873 shares — an estimated $514K sold.

Ascend Capital first reported a position in ASMB in Q1 2018 and held it in 1 quarter. The position peaked at $514K in Q1 2018. 105 funds tracked by Wall St. Rank hold ASMB as of Q2 2018.

Ascend Capital reported no remaining Assembly Biosciences position as of Q2 2018 after selling out during the quarter.
Ascend Capital sold 873 Assembly Biosciences shares in Q2 2018, an estimated $514K.
Ascend Capital first reported a position in Assembly Biosciences in Q1 2018 and held it in 1 quarter.
Ascend Capital's Assembly Biosciences position peaked at $514K in Q1 2018.
105 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.